

Eric P Winer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6615708/publications.pdf>

Version: 2024-02-01

209
papers

36,347
citations

9428

76
h-index

4035

182
g-index

212
all docs

212
docs citations

212
times ranked

36331
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097
2	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785
3	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
4	Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. <i>Journal of Clinical Oncology</i> , 2013, 31, 2382-2387.	0.8	998
5	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017, 548, 471-475.	13.7	998
6	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 971-977.	13.9	958
7	Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1145-1153.	0.8	860
8	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	5.1	826
9	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
10	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
11	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 13-21.	0.8	782
12	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752.	0.8	771
13	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3764-3773.	3.2	733
14	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2014, 32, 2255-2269.	0.8	661
15	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	13.9	621
16	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	13.9	598
17	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
18	Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing. <i>Journal of Clinical Oncology</i> , 2001, 19, 2875-2882.	0.8	574

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489.	0.8	543
20	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1207-1214.	5.1	523
21	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
22	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016, 529, 413-417.	13.7	490
23	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. <i>Cancer</i> , 2012, 118, 5463-5472.	2.0	469
24	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
25	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1460-1468.	0.8	413
26	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-438.	0.8	384
27	Adjuvant Chemotherapy in Older and Younger Women With Lymph Node-Positive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1073.	3.8	371
28	Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 884-890.	0.8	365
29	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016, 29, 255-269.	7.7	356
30	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
31	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	0.8	351
32	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	0.8	336
33	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. <i>Journal of Clinical Oncology</i> , 2012, 30, 3234-3241.	0.8	319
34	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	0.8	303
35	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 3308-3314.	0.8	297
36	Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. <i>Journal of Clinical Oncology</i> , 2007, 25, 3699-3704.	0.8	282

#	ARTICLE	IF	CITATIONS
37	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
38	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	5.1	260
39	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	0.8	254
40	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3840-3847.	0.8	253
41	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , 2016, 34, 1689-1701.	0.8	243
42	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2254-2261.	0.8	232
43	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
44	Complications of axillary lymph node dissection for carcinoma of the breast. <i>Cancer</i> , 1998, 83, 1362-1368.	2.0	221
45	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
46	CDK4/6 inhibition in breast cancer: current practice and future directions. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878645.	1.4	218
47	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2142-2150.	0.8	207
48	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. <i>Cancer Cell</i> , 2018, 33, 173-186.e5.	7.7	201
49	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	0.8	197
50	Olaparib and \pm -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	5.1	191
51	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1057-1065.	1.1	183
52	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1174-1193.	7.7	176
53	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
54	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171

#	ARTICLE	IF	CITATIONS
55	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
56	Acquired <i>HER2</i> mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. <i>Nature Genetics</i> , 2019, 51, 207-216.	9.4	170
57	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
58	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	0.8	165
59	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
60	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	0.8	148
61	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	0.8	141
62	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with <i>PIK3CA</i> or AKT mutations, and/or <i>PTEN</i> loss/ <i>PTEN</i> mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	2.2	141
63	Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	3.2	138
64	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 316.	3.8	115
65	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	3.2	109
66	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2710-2717.	0.8	108
67	Combination inhibition of <i>PI3K</i> and <i>mTORC1</i> yields durable remissions in mice bearing orthotopic patient-derived xenografts of <i>HER2</i> -positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	15.2	105
68	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	0.8	101
69	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. <i>Journal of Clinical Oncology</i> , 2017, 35, 1008-1008.	0.8	99
70	Phase II study of ruxolitinib, a selective <i>JAK1/2</i> inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 10.	2.3	95
71	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	0.8	93
72	Impact of <i>HER2</i> Heterogeneity on Treatment Response of Early-Stage <i>HER2</i> -Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	7.7	92

#	ARTICLE	IF	CITATIONS
73	Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3249-3259.	3.2	88
74	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
75	Randomized trial of a physical activity intervention in women with metastatic breast cancer. <i>Cancer</i> , 2016, 122, 1169-1177.	2.0	87
76	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5974-5989.	3.2	87
77	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	3.4	84
78	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus Nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	3.0	83
79	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3809-3815.	0.7	81
80	Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. <i>Journal of Clinical Oncology</i> , 2014, 32, 2318-2327.	0.8	80
81	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	80
82	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 25-32.	1.9	79
83	Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer—CALGB 40302 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 3959-3966.	0.8	77
84	Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. <i>Journal of Clinical Oncology</i> , 2012, 30, 4071-4076.	0.8	76
85	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisisb for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
86	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	3.2	76
87	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
88	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	0.8	74
89	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5292-5304.	3.2	73
90	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 2311-2317.	0.8	70

#	ARTICLE	IF	CITATIONS
91	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
92	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	68
93	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. <i>Clinical Cancer Research</i> , 2018, 24, 1795-1804.	3.2	67
94	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3053-3060.	3.2	66
95	Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). <i>Journal of Oncology Practice</i> , 2014, 10, e285-e292.	2.5	65
96	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage IIâ€“III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016, 160, 297-304.	1.1	63
97	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	0.8	62
98	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	2.2	60
99	IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1003-1003.	0.8	59
100	Pharmacokinetics and clinical impact of all- trans retinoic acid in metastatic breast cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 335-341.	1.1	55
101	Phase 2 study of pembrolizumab as first-line therapy for PD-L1â€“positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1088-1088.	0.8	55
102	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	52
103	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	0.8	52
104	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
105	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expressionâ€“Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 6039-6050.	3.2	48
106	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	2.2	48
107	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	5.7	48
108	I-SPY 2 â€” Toward More Rapid Progress in Breast Cancer Treatment. <i>New England Journal of Medicine</i> , 2016, 375, 83-84.	13.9	47

#	ARTICLE	IF	CITATIONS
109	Breast cancerâ€™specific survival by age: Worse outcomes for the oldest patients. <i>Cancer</i> , 2018, 124, 2184-2191.	2.0	46
110	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 1108-1114.	1.2	44
111	Androgen Receptor Expression and Breast Cancer Survival: Results From the Nursesâ€™ Health Studies. <i>Journal of the National Cancer Institute</i> , 2019, 111, 700-708.	3.0	44
112	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 238-245.	1.1	44
113	Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. <i>Cancer</i> , 2008, 112, 700-709.	2.0	43
114	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1013-1013.	0.8	42
115	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptorâ€™Positive, Human Epidermal Growth Factor Receptor 2â€™Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	0.8	42
116	Is Axillary Lymph Node Dissection Indicated for Early-Stage Breast Cancer? A Decision Analysis. <i>Journal of Clinical Oncology</i> , 1999, 17, 1465-1465.	0.8	41
117	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 305-312.	1.1	37
118	Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. <i>Oncologist</i> , 2019, 24, e441-e449.	1.9	36
119	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	0.8	36
120	Perils of the Pathologic Complete Response. <i>Journal of Clinical Oncology</i> , 2016, 34, 3959-3962.	0.8	35
121	TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1002-1002.	0.8	35
122	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€™Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
123	Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy. <i>Cancer</i> , 2005, 104, 1580-1589.	2.0	34
124	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2020, 80, PD5-03-PD5-03.	0.4	34
125	Temporal and spatial topography of cell proliferation in cancer. <i>Nature Cell Biology</i> , 2022, 24, 316-326.	4.6	34
126	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 4120-4129.	0.8	32

#	ARTICLE	IF	CITATIONS
127	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	3.2	31
128	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	30
129	Localâ€“regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
130	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. <i>Journal of Clinical Oncology</i> , 2020, 38, 504-504.	0.8	30
131	Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. , 1999, 8, 167-176.		29
132	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	3.2	29
133	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 983-991.	3.2	29
134	Quality-of-life research in patients with breast cancer. <i>Cancer</i> , 1994, 74, 410-415.	2.0	27
135	Surveillance Mammography in Older Patients With Breast Cancerâ€“Can We Ever Stop?. <i>JAMA Oncology</i> , 2017, 3, 402.	3.4	27
136	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	1.1	27
137	Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. <i>Breast</i> , 2015, 24, S132-S135.	0.9	26
138	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 113-123.	1.1	26
139	Heterogeneity of breast cancer and implications of adjuvant chemotherapy. <i>Breast Cancer</i> , 2008, 15, 31-34.	1.3	24
140	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	3.2	24
141	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	0.8	22
142	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22
143	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
144	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	20

#	ARTICLE	IF	CITATIONS
145	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20
146	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 500-500.	0.8	20
147	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015, 20, 713-718.	1.9	19
148	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	5.8	19
149	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	2.3	18
150	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020, 13, 1055-1062.	0.7	17
151	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. <i>Clinical Breast Cancer</i> , 2014, 14, 413-416.	1.1	16
152	Timeliness in Breast Cancer Treatment—The Sooner, the Better. <i>JAMA Oncology</i> , 2016, 2, 302.	3.4	16
153	A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1046-1046.	0.8	16
154	Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. <i>Annals of Surgical Oncology</i> , 2015, 22, 4280-4286.	0.7	15
155	De-escalating Breast Cancer Surgery—Where Is the Tipping Point?. <i>JAMA Oncology</i> , 2020, 6, 183.	3.4	15
156	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	3.4	15
157	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz096.	1.4	14
158	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13
159	Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer. <i>Breast Disease</i> , 2001, 14, 41-50.	0.4	12
160	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. <i>Leukemia</i> , 2022, 36, 210-220.	3.3	12
161	Informed Consent for BRCA1 and BRCA2 Testing. <i>Breast Disease</i> , 1998, 10, 99-114.	0.4	11
162	A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. <i>Journal of Geriatric Oncology</i> , 2013, 4, 353-361.	0.5	11

#	ARTICLE	IF	CITATIONS
163	ALEXANDRA/Impassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS597-TPS597.	0.8	11
164	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 117-124.	0.4	11
165	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	0.6	11
166	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	1.5	11
167	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research and Treatment, 2021, 185, 215-227.	1.1	10
168	Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer, 2021, 21, 568.	1.1	10
169	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal of the National Cancer Institute, 2021, 113, 355-359.	3.0	10
170	p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications, 2022, 13, 1473.	5.8	10
171	The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage IIâ€”III and metastatic breast cancers. Breast Cancer Research and Treatment, 2022, 194, 65-78.	1.1	10
172	Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1â€” metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, TPS1106-TPS1106.	0.8	9
173	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist, 2015, 20, 992-1000.	1.9	8
174	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multiâ€”institutional study. Cancer, 2015, 121, 1937-1948.	2.0	8
175	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Journal of the American College of Surgeons, 2017, 224, 688-694.	0.2	8
176	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum, 2021, 5, pkab025.	1.4	8
177	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. Journal of Clinical Oncology, 2020, 38, 1005-1005.	0.8	8
178	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
179	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clinical Breast Cancer, 2020, 20, 395-401.e3.	1.1	7
180	Expanding Criteria for Prognostic Stage IA in Hormone Receptorâ€”Positive Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1744-1750.	3.0	7

#	ARTICLE	IF	CITATIONS
181	T-DM1 – an important agent in the history of breast cancer management. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 651-652.	12.5	6
182	Predicting breast cancer therapeutic response. <i>Nature Medicine</i> , 2018, 24, 535-537.	15.2	6
183	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e20-e26.	1.1	5
184	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 45-52.	0.4	5
185	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1777-1787.	1.5	5
186	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. <i>Breast</i> , 2016, 30, 136-140.	0.9	4
187	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
188	Inability to escalate vinorelbine dose intensity using a daily 3 schedule with and without filgrastim in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 68-72.	1.1	3
189	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 316-324.	2.3	3
190	Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 551-552.	3.0	3
191	Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119. , 2021, , .		3
192	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1102-TPS1102.	0.8	3
193	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ – Reply. <i>JAMA Oncology</i> , 2020, 6, 1118.	3.4	3
194	Perceptions of patients with early stage breast cancer toward research biopsies. <i>Cancer</i> , 2021, 127, 1208-1219.	2.0	3
195	Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. <i>JCO Oncology Practice</i> , 2022, 18, e1447-e1453.	1.4	3
196	Case 32-2007. <i>New England Journal of Medicine</i> , 2007, 357, 1640-1648.	13.9	2
197	Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature. <i>Cancer Treatment Communications</i> , 2015, 4, 41-45.	0.4	2
198	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2145-2156.	1.6	2

#	ARTICLE	IF	CITATIONS
199	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2 ⁺ breast cancer. <i>Cancer Research</i> , 2022, 82, GS2-01-GS2-01.	0.4	2
200	Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. <i>Journal of the National Cancer Institute</i> , 2018, 110, 443-445.	3.0	1
201	ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600.	0.8	1
202	Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2017, 35, 1746-1747.	0.8	0
203	Temporal and spatial topography of cell proliferation in cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3122-3122.	0.8	0
204	Survival in male breast cancer (MaBC) over the past three decades.. <i>Journal of Clinical Oncology</i> , 2021, 39, 569-569.	0.8	0
205	Reply to M. Tanaka et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01967.	0.8	0
206	Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 514-514.	0.8	0
207	Genomic profiling of breast cancer brain metastases reveals targetable alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2525-2525.	0.8	0
208	Expanding criteria for prognostic stage IA disease in HR+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 550-550.	0.8	0
209	The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 573-4.	0.3	0